Suzhou Basecare Medical (HKSE:02170) 3-Year Revenue Growth Rate : 32.10% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Suzhou Basecare Medical 3-Year Revenue Growth Rate?

Suzhou Basecare Medical's Revenue per Share for the six months ended in Dec. 2023 was HK$0.49.

During the past 12 months, Suzhou Basecare Medical's average Revenue per Share Growth Rate was 44.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 32.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 40.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 6 years, the highest 3-Year average Revenue per Share Growth Rate of Suzhou Basecare Medical was 52.70% per year. The lowest was 32.10% per year. And the median was 35.30% per year.

Competitive Comparison of Suzhou Basecare Medical's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Suzhou Basecare Medical's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Suzhou Basecare Medical's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Suzhou Basecare Medical's 3-Year Revenue Growth Rate falls into.

Suzhou Basecare Medical 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Suzhou Basecare Medical (HKSE:02170) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Suzhou Basecare Medical 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Suzhou Basecare Medical's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Basecare Medical (HKSE:02170) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Suzhou Basecare Medical Corp Ltd (HKSE:02170) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

BioBay, No. 218 Xinghu Street, Unit 101, Building A3, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000

Website

https://www.basecare.cn

Suzhou Basecare Medical Corp Ltd is engaged in providing genetic testing solutions for assisted human reproduction. The company generates revenues from Sales of testing kits, followed by Sales of testing devices and instruments. Basecare focuses on the assisted reproductive sector, such as pre-implantation genetic screening and diagnosis, non-invasive prenatal DNA testing, and chromosome abnormalities testing. It generates revenue from China.

Executives

Orbimed Capital Llc	2102 Investment manager
Lake Bleu Prime Healthcare Master Fund Limited	2201 Interest of corporation controlled by you
Orbimed Partners Master Fund Limited	2101 Beneficial owner
Dawn Capital Fund	2101 Beneficial owner
Dawn Capital Limited	2102 Investment manager
Hh Spr-xiv Cy Holdings Limited	2201 Interest of corporation controlled by you
Hh Spr-xiv Hk Holdings Limited	2101 Beneficial owner
Hh Spr-xiv Holdings L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager

Suzhou Basecare Medical (HKSE:02170) Headlines

No Headlines